Galecto (GLTO) awards RSUs and large stock option grant to CMO Becker

Rhea-AI Filing Summary

Galecto, Inc. reported new equity awards to Chief Medical Officer Hewes L. Becker. On January 5, 2026, Becker received 264,629 restricted stock units, each representing one share of Galecto common stock at settlement. These RSUs vest 25% on each anniversary of the grant date over four years, conditioned on continued service.

On the same date, Becker was granted a stock option covering 528,603 shares of common stock at an exercise price of $21.82 per share. The option vests 25% on January 5, 2027 and then in equal monthly installments through January 5, 2030, also subject to continued service. Following these grants, Becker directly holds 264,629 shares of common stock and options for 528,603 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hewes L. Becker

(Last) (First) (Middle)

C/O GALECTO, INC.,

221 CRESCENT ST, BUILDING 23, SUITE 105

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Galecto, Inc. [ GLTO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	01/05/2026		A		264,629	A	$0	264,629	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$21.82	01/05/2026		A		528,603		(2)	01/05/2036	Common Stock	528,603	$0.00	528,603	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents the right to receive, at settlement, one share of common stock of the Issuer. The RSUs will vest with respect to 25% on each anniversary of the grant date through the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

2. This option represents a right to purchase shares of common stock of the Issuer. This option will vest as to 25% on January 5, 2027 and in equal monthly installments thereafter through January 5, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Lori Firmani, attorney-in-fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did GLTO report for Hewes L. Becker?

The report shows that Hewes L. Becker, Galecto's Chief Medical Officer, received grants of 264,629 restricted stock units and a stock option for 528,603 shares of common stock on January 5, 2026.

How many GLTO restricted stock units were granted to the Chief Medical Officer?

Becker was granted 264,629 restricted stock units, each representing the right to receive one share of Galecto, Inc. common stock upon settlement.

What are the vesting terms for Hewes L. Becker’s RSUs at Galecto (GLTO)?

The 264,629 RSUs vest 25% on each anniversary of the January 5, 2026 grant date over four years, subject to Becker’s continued service with Galecto on each vesting date.

What stock option grant did Galecto’s Chief Medical Officer receive?

Becker received a stock option to purchase 528,603 shares of Galecto common stock at an exercise price of $21.82 per share, reported as a direct holding.

How do the GLTO stock options granted to Hewes L. Becker vest?

The option vests as to 25% of the shares on January 5, 2027, with the remaining shares vesting in equal monthly installments through January 5, 2030, contingent on continued service.

How many Galecto (GLTO) shares and options does Hewes L. Becker hold after these grants?

After the reported grants, Becker beneficially owns 264,629 shares of common stock and holds stock options for an additional 528,603 shares, all reported as held directly.

Were these GLTO equity awards to the Chief Medical Officer granted for cash consideration?

The filing lists the acquisition price for both the 264,629 RSUs and the stock option covering 528,603 shares as $0.00, indicating they were granted without cash paid at grant.